A randomized trial of bevacizumab, an anti-vascular
endothelial growth factor antibody, for metastatic renal cancer.
Not exact matches
Bevacizumab, a monoclonal
antibody, is an angiogenesis inhibitor that targets a chemical signal, vascular
endothelial growth factor A (VEGF - A).
↵ 3 The abbreviations used are: HUVEC, human umbilical vein
endothelial cell; DiI - Ac - LDL, 1,1 ′ - dioctadecyl - 3,3,3 ′, 3 ′ - tetramethyl - indocarbocyanine acetylated low - density lipoprotein; FACS, fluorescence - activated cell sorting; FGFR, fibroblast
growth factor receptor; Flk, fetal liver kinase; ICAM, intercellular adhesion molecule; mAb, monoclonal
antibody; PE, phycoerythrin; TNF, tumor necrosis
factor; VCAM, vascular cell adhesion molecule.
A phase I trial of ramucirumab, a human monoclonal
antibody against the vascular
endothelial growth factor - 2 (VEGFR - 2) receptor, in children with refractory solid tumors, including CNS tumors (NCT02564198).
A phase I trial of ramucirumab, a human monoclonal
antibody against the vascular
endothelial growth factor - 2 (VEGFR - 2) receptor, in children with refractory solid tumors, including CNS tumors -LRB-
The use of targeting
antibodies against vascular
endothelial growth factor (VEGF), a protein that promotes tumor
growth and spread, plus chemotherapy has prolonged disease free survival in several different tumor types in man.
In this proposal we set out to utilize our canine - derived scFv phage display platform technology to isolate canine
antibody fragments that bind and neutralize Vascular
Endothelial Growth Factor (VEGF).